Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib for lung cancer with ROS1 fusions and how to treat them.
Ben Levy, MD, clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib (Xalkori) for lung cancer with ROS1 fusions and how to treat them.
Levy says there are 2 drugs that target the G2032R mutation. One is lorlatinib (Lorbrena), which has already been approved for patients with ALK-positive lung cancer. It showed a 30% to 40% response rate in crizotinib-refractory patients with ROS1 and activity in the G2032R mutation.
The other drug is repotrectinib, which has not received any approvals yet. Levy explains that this agent is also specifically designed to overcome the G2032R mutation. Data from the 2019 American Society of Clinical Oncology Annual Meeting showed meaningful responses of about 40% in patients who were refractory to crizotinib as well as responses in the brain.
It important that contemporary diagnostics platforms such as an RNA and DNA next-generation sequencing platform are deployed in this setting to interrogate ROS1 in patients, according to Levy. For patients with ROS1-rearranged lung cancer, crizotinib and entrectinib (Rozlytrek) are approved treatments and have shown response rates of over 70% with a progression-free survival of about 19 months in competitive outcomes. Entrectinib also showed an intracranial response.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More